4E2 Stock Overview A clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Relmada Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Relmada Therapeutics Historical stock prices Current Share Price US$0.51 52 Week High US$6.35 52 Week Low US$0.51 Beta 0.33 1 Month Change -80.97% 3 Month Change -82.77% 1 Year Change -81.39% 3 Year Change -97.41% 5 Year Change n/a Change since IPO -98.76%
Recent News & Updates
Relmada Therapeutics to Discontinue the Reliance Ii and Relight Phase 3 Studies of Rel-1017 Dec 10
Relmada Therapeutics, Inc. Announces Phase 3 Reliance II Trial Is Futile at Its Interim Analysis and Is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance Dec 04
Relmada Therapeutics, Inc. Initiates Phase 1 Dosing with Rel-P11 for Metabolic Disease Nov 15
New major risk - Financial position Nov 09
New major risk - Revenue and earnings growth Nov 08
Relmada Therapeutics, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Nov 05 See more updates
Relmada Therapeutics to Discontinue the Reliance Ii and Relight Phase 3 Studies of Rel-1017 Dec 10
Relmada Therapeutics, Inc. Announces Phase 3 Reliance II Trial Is Futile at Its Interim Analysis and Is Unlikely to Meet the Primary Efficacy Endpoint with Statistical Significance Dec 04
Relmada Therapeutics, Inc. Initiates Phase 1 Dosing with Rel-P11 for Metabolic Disease Nov 15
New major risk - Financial position Nov 09
New major risk - Revenue and earnings growth Nov 08
Relmada Therapeutics, Inc. to Report Q3, 2024 Results on Nov 07, 2024 Nov 05
CEO & Director recently bought €359k worth of stock Sep 12
New major risk - Share price stability Aug 09
New major risk - Revenue and earnings growth Aug 08
Relmada Therapeutics, Inc. to Report Q2, 2024 Results on Aug 07, 2024 Aug 05
New major risk - Revenue and earnings growth May 09
Relmada Therapeutics, Inc. to Report Q1, 2024 Results on May 08, 2024 May 08
Relmada Therapeutics, Inc., Annual General Meeting, May 24, 2024 Apr 10
Relmada Therapeutics, Inc. to Report Fiscal Year 2023 Results on Mar 19, 2024 Mar 13
CEO & Director recently bought €356k worth of stock Feb 01
Relmada Therapeutics, Inc. to Report Q3, 2023 Results on Nov 08, 2023 Nov 04
Relmada Therapeutics to Present New Preclinical Data on Its Psilocybin Program At AASLD the Liver Meeting 2023 Oct 12
Relmada Therapeutics, Inc. Announces Dosing of First Patient in Relight, a Phase 3 Trial of Relight, a Phase 3 Trial of Relight for the Adjunctive Treatment of Major Depressive Disorder Aug 24
New major risk - Revenue and earnings growth Aug 10
Relmada Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023 Aug 03 Relmada Therapeutics, Inc.(NasdaqGS:RLMD) dropped from Russell Small Cap Comp Value Index
Relmada Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023 May 09
Relmada Therapeutics, Inc. Appoints Fabiana Fedeli to Board of Directors Jan 13
Relmada Therapeutics, Inc. Appoints Cedric O'Gorman MD as Chief Medical Officer Jan 10
CEO & Director recently bought €110k worth of stock Dec 14
Relmada Therapeutics, Inc. Announces Top-line Results from Phase 3 RELIANCE I Trial for REL-1017 as an Adjunctive Treatment for Major Depressive Disorder Dec 08
High number of new and inexperienced directors Nov 16
Relmada Therapeutics, Inc. to Report Q3, 2022 Results on Nov 10, 2022 Nov 09
Relmada Therapeutics Inc. Announces Top-line Results from Phase 3 RELIANCE III Trial for REL 1017 as a Monotherapy for the Treatment of Major Depressive Disorder Oct 14
Relmada Therapeutics Announces Completion of Treatment in Company's Registrational Phase 3 Reliance III Trial for REL-1017 as A Monotherapy for Major Depressive Disorder Sep 21
Relmada Therapeutics Receives FDA Fast Track Designation for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder Aug 10
Relmada Therapeutics, Inc. to Report Q2, 2022 Results on Aug 11, 2022 Aug 06
Relmada Therapeutics, Inc. Appoints John Hixon as Head of Commercial Jul 22
Relmada Therapeutics, Inc. Announces Publication of REL-1017 Preclinical Data in Frontiers in Pharmacology May 02
High number of new and inexperienced directors Apr 27
Relmada Therapeutics, Inc., Annual General Meeting, May 25, 2022 Apr 12
Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 VS Ketamine for Abuse Potential Feb 24
Relmada Therapeutics, Inc. Announces Publication of Rel-1017 Phase 2 Study Results in the American Journal of Psychiatry Dec 23
Relmada Therapeutics, Inc. Announces Poster Presentation at the American Society for Pharmacology and Experimental Therapeutics Annual Meeting at Experimental Biology 2021 Apr 28
Relmada Therapeutics, Inc. to Report Q4, 2020 Results on Mar 23, 2021 Mar 19
New 90-day high: €31.40 Feb 18
New 90-day high: €30.80 Jan 14
Relmada Therapeutics, Inc. Announces Resignation of Thomas Wessel as Executive Vice President and Head of Research and Development Jan 06
Relmada Therapeutics, Inc. Announces Initiation of Phase 3 Program for REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder Dec 10
Relmada Therapeutics Announces Appointments of New Executive Oct 29
New 90-day low: €28.20 Oct 21
New 90-day low - €30.00 Aug 26
New 90-day low - €32.60 Jul 28 Shareholder Returns 4E2 DE Pharmaceuticals DE Market 7D 0% -2.2% -2.0% 1Y -81.4% -15.8% 6.8%
See full shareholder returns
Return vs Market: 4E2 underperformed the German Market which returned 6.8% over the past year.
Price Volatility Is 4E2's price volatile compared to industry and market? 4E2 volatility 4E2 Average Weekly Movement 26.5% Pharmaceuticals Industry Average Movement 5.4% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.4% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 4E2's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 4E2's weekly volatility has increased from 18% to 26% over the past year.
About the Company Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.
Show more Relmada Therapeutics, Inc. Fundamentals Summary How do Relmada Therapeutics's earnings and revenue compare to its market cap? 4E2 fundamental statistics Market cap €11.02m Earnings (TTM ) -€83.18m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 4E2 income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$86.49m Earnings -US$86.49m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/24 12:28 End of Day Share Price 2024/12/05 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Relmada Therapeutics, Inc. is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Robert LeBoyer Aegis Capital Corporation Maxim Jacobs Edison Investment Research Yatin Suneja Guggenheim Securities, LLC
Show 6 more analysts 
